IMM 11.9% 29.5¢ immutep limited

prr vs nrt product differences, page-3

  1. 244 Posts.
    PRR:
    - cvac already in phase II/III clinical trial, hopefully a couple of years away from fda approval (fingers crossed).
    - based on a technology already approved, with improvements in methodology, hopefully increasing efficacy
    - designed for muc-1 cancers, namely ovarian, hopefully others in the future

    NRT:
    - new laboratory based drug, recently patented
    - yet to start human trials, as kbear stated, a decade away from approval
    - would most likely target brain cancer
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
29.5¢
Change
-0.040(11.9%)
Mkt cap ! $428.5M
Open High Low Value Volume
32.0¢ 33.0¢ 28.0¢ $7.278M 23.75M

Buyers (Bids)

No. Vol. Price($)
4 53192 29.5¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 41048 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.